In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...

Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...

Learn how incorporating real-world data at study design can improve feasibility, reduce amendments, and align eligibility ...

In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class ...

Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

New post hoc and pooled analyses from the OASIS 4 trial presented at ObesityWeek 2025 show that oral semaglutide 25 mg improves glycemic control, cardiovascular risk factors, and weight outcomes ...

In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...

In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore ...

Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...